The analyzed cohort of our tertiary IBD care center is characterized by relatively severe and refractory disease courses with a history of CD-related surgical interventions in 53% and a history of immunomodulatory treatment and anti-TNFα treatment in 91.6 and 80.7% of the included CD patients, respectively. This evidence concerns the gene TNF and inflammatory bowel disease.